Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan. Issue 1 (18th September 2021)

• Record Type: Journal Article
• Authors: Nishioka, Kinue; Makimura, Tomomi; Ishiguro, Akihiro; Nonaka, Takahiro; Yamaguchi, Mitsune; Uyama, Yoshiaki
• Is Part Of: Clinical pharmacology & therapeutics. Volume 111:Issue 1(2022)
• Page Start: 35
• Page End: 43
• Publication Date: 2021-09-18
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.2410
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : There is growing interest in the utilization of real‐world data (RWD) and real‐world evidence (RWE) for regulatory purposes. However, there are challenges in the practical utilization of RWD to provide RWE as a basis for regulatory decision making. This article presents the regulatory initiatives in Japan and efforts taken to promote the utilization of RWD/RWE for regulatory decision making at the pre‐ and postapproval stages of a drug. There has been a rapid increase in the number of RWD cases evaluated for drug safety assessment in Japan. Nevertheless, more regulatory experiences and considerations are necessary for the utilization of RWD in the efficacy evaluation of a drug. Based on past experiences, data reliability and appropriateness of the methodology for analysis are the major discussion points in utilizing RWD and RWE for regulatory decision making. International harmonization of regulatory requirements is another important area in utilizing RWD and sharing the RWE globally. We describe our perspective on providing RWE, which is useful for regulatory decision making throughout a drug's life cycle.